Last reviewed · How we verify

Idamycin Pfs (Idarubicin Hydrochloride)

Pfizer Inc. · FDA-approved approved Small molecule Quality 62/100

Idarubicin forms DNA complexes, inhibits nucleic acid synthesis and topoisomerase II, produces DNA-damaging free radicals.

Idarubicin is an anthracycline topoisomerase inhibitor approved for adult acute myeloid leukemia as part of combination chemotherapy. The drug demonstrates potent cytotoxic activity through DNA binding and topoisomerase II inhibition with rapid distribution to leukemic cells. Idarubicin undergoes hepatic metabolism to active idarubicinol with sustained plasma levels exceeding 8 days, requiring careful monitoring. No absolute contraindications exist, though effects in renal or hepatic impairment remain unknown.

At a glance

Generic nameIdarubicin Hydrochloride
SponsorPfizer Inc.
Drug classAnthracycline topoisomerase inhibitor
TargetDNA, Topoisomerase II
ModalitySmall molecule
PhaseFDA-approved
First approval1990

Mechanism of action

Idarubicin hydrochloride exhibits antimitotic and cytotoxic activity through multiple mechanisms of action. The drug forms complexes with DNA and inhibits nucleic acid synthesis, preventing cell replication. Additionally, idarubicin inhibits topoisomerase II activity and generates DNA-damaging free radicals, leading to cell death in rapidly dividing leukemic cells.

Approved indications

Common side effects

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: